15% Off
15% Off
marketed by NATCO SPL.DIV
• 30TAB
₹8491.50
M.R.P.: ₹9990
15% Off
Inclusive of all taxes
Erlonat belongs to an antineoplastic class of medication. It is used to treat non-small cell lung cancer and pancreatic cancer (locally advanced or spread to other body areas). Erlonat attaches to the chemical messenger epidermal growth factor receptors and stops the action of an abnormal protein that enables the cancer cells to multiply. Thus it regulates the growth of the cancer cells. Non
Hypersensitivity.
Babies: Safety and efficacy studies have not been well established in children.
Pregnancy: This medicine is not safe to use in pregnancy.
Evidence-based studies have shown that it causes toxic effects on developing babies.
Your doctor may prescribe this medicine when the benefits outweigh the risks in an unavoidable situation.
Seek your doctor's advice.
Lactating mother: This medicine is not safe to use in lactating mothers.
Limited studies have shown that it causes toxic effects on babies.
Seek your doctor's advice.
Alcohol: It is not known whether to use this medicine while consuming alcohol.
Driving: It is not known whether to use this medicine while driving.
Avoid driving if you have any symptoms.
Kidney: This medicine is safe to use in kidney disease patients.
It is not advised to use in patients with severe kidney disease.
No dose adjustment is needed.
Seek your doctor's advice.
Liver: This medicine should be used with caution in patients with severe liver disease.
You may require dosage adjustment.
Seek doctor's advice.
You may not need dose adjustment in mild to moderate liver disease patients..
Abdominal pain Bone pain Breathlessness Constipation Cough Diarrhoea Fatigue Fever Infection Muscle pain Nausea Rash Mouth inflammation Vomiting Weight loss.
Erlonat belongs to an antineoplastic class of medication.
Erlonat attaches to the chemical messenger epidermal growth factor receptors and stops the action of an abnormal protein that enables the cancer cells to multiply.
Thus it regulates the growth of the cancer cells..
If you miss a dose, take it as soon as possible.
If it is near the time of the next dose, then skip the missed dose.
Take the prescribed dose on your regular time daily.
Don't double the dose to catch up with the missed dose..
• This medicine is prescribed to treat non-small cell lung cancer and pancreatic cancer (locally advanced, or has spread to other areas of the body) • Take this medicine 1 hour before or 2 hours after your meals • You may experience diarrhoea as a side effect of this medicine. To avoid dehydration, drink plenty of fluids • Tell your doctor if you observe blood in stools • Use effective contraceptive methods to avoid pregnancy during the treatment and also up to a month even after completion of your treatment • Avoid exposure to direct sunlight and wear protective clothing while heading out as this medicine makes your skin sensitive to sunlight • If you are a smoker, avoid smoking as it makes treatment ineffective • Avoid antacids, h2 blockers, including ranitidine, as they may interfere with this medicine • Notify your doctor if you experience mouth ulcers, vision disturbances, cough, breathing difficulty during this treatment • Your physician may advise you to undergo regular liver function tests during the treatment • Avoid this medicine if you are pregnant, intend to be pregnant, or breastfeeding.
Major • Erlonat + Acenocoumarol: Concurrent use of these medicines may result in an increased risk of bleeding • Erlonat + Amiodarone: Concurrent use of these medicines may result in neurotoxicity • Erlonat + Indinavir: Concurrent use of these medicines may result in increased erlonat exposure and risk of toxicity • Erlonat + Itraconazole: Concurrent use of these medicines may result in increased erlonat exposure and risk of toxicity • Erlonat + Lopinavir: Concurrent use of these medicines may result in increased erlonat exposure and risk of toxicity • Erlonat + Pantoprazole: Concurrent use of these medicines may result in decreased erlonat exposure • Erlonat + Phenytoin: Concurrent use of these medicines may result in decreased erlonat exposure Moderate • Erlonat + Magaldrate: Concurrent use of these medicines may result in decreased erlonat exposure • Erlonat + Mifepristone: Concurrent use of these medicines may result in increased erlonat exposure .
100% Authentic
Easy Return